✦ LIBER ✦

P88 Neoadjuvant chemotherapy with infusional 5-Fluorouracil, Doxorubicin and cyclophosphamide in locally advanced breast cancer and c-erb-B2 as a prognostic indicator

✍ Scribed by H. Jeung; S. Rha; Y. Moon; Y. Choi; W. Yang; C. Suh; J. Roh; G. Kim; H. Chung

Book ID: 114315811
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 154 KB
Volume: 14
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(05)80124-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neoadjuvant chemotherapy with cyclophosp

Neoadjuvant chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 69 cases of locally advanced (stage IIIb) breast cancer

✍ Pankaj Gupta; Loveleen Bilani; Gaur K. Rath; Anoop Misra; Mahesh C. Mishra; Nuta 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 340 KB

Acute arterial thrombosis in a patient w

Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5-fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin-3

✍ C. Theodossiou; G. Kroog; S. Ettinghausen; A. Tolcher; K. Cowan; J. O'Shaughness 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB 👁 2 views

A phase III trial of taxotere and doxoru

A phase III trial of taxotere and doxorubicin (AT) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in patients with unresectable locally advanced breast cancer: an interim analysis

✍ K. Bouzid; J. Vinholes; F. Salas; E. Mickiewicz; S. Valdivia; V. Ostapenko; E. B 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 182 KB

A combination therapy with mitomycin c,

A combination therapy with mitomycin c, etoposide, doxifluridine and medroxyprogesterone acetate as second line therapy for advanced breast cancer refractory to combination chemotherapy of cyclophosphamide, doxorubicin and 5 fluorouracil

✍ Katsumasa Kuroi; Akihiko Osaki; Hiroyuki Kawami; Shigeru Murakami; Tetsuya Toge 📂 Article 📅 1997 🏛 Springer Japan 🌐 English ⚖ 374 KB

PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WI

PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN FRANCE

✍ H Miadi-Fargier; C Le Pen; MC Woronoff-Lemsi; JP Guastalla; X Pivot; H Roché; F 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Multimodality treatment of 128 patients

Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide : Prognostic and therapeutic implications

✍ Ylva A. Karlsson; Per O. Malmström; Thomas Hatschek; Tommy G. Fornander; Martin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB 👁 2 views

## BACKGROUND. Locally advanced breast carcinoma is associated with a poor prognosis. With single treatment modalities, i.e., surgery and/or radiation therapy, results have been consistently dismal. However, several earlier reports have indicated improvement in survival with a combined modality ap